Double dose, shorter gap for Pfizer vaccine to be effective against Delta: Lancet

Mini

The antibody response to the Delta variant is lower in people who have received just one dose and a longer gap between doses may significantly reduce antibodies against this variant, the study said.

Double dose, shorter gap for Pfizer vaccine to be effective against Delta: Lancet

A new study in the Lancet journal has found that the Pfizer-BioNTech’s vaccine isn’t as effective against the Delta variant, first detected in India (B.1.617.2), and needs two doses to offer any protection.

The antibody response to the Delta variant is lower in people who have received just one dose and a longer gap between doses may significantly reduce antibodies against this variant, the study said.

Lancet said the Pfizer vaccine produces five times fewer antibodies against the Delta variant compared to those against the original COVID-19 strain. The vaccine produces fewer antibodies with increasing age and the levels decline over time, Lancet says.

The Delta variant is now spreading in the UK and early evidence suggests there may be an "increased risk of hospitalisation" with the Delta strain compared to the Alpha and the Lancet study supports the UK's plans to reduce the gap between the two doses of the vaccine.

According to a report in Live Mint, the Lancet study used the Pfizer–BioNTech vaccine against five COVID-19 strains. The variants used were B.1.617.2 (Delta) and B.1.351 (Beta), first detected in South Africa.

Apart from these two, a strain with the original spike sequence (Wild-type); a strain with an Asp614Gly mutation isolated during the first wave of infection in the UK (D614G); and B.1.1.7 (Alpha) was also investigated.

What has been found was six (3 percent) and nine (5 percent) of the 159 participants who had agreed to be vaccinated lacked antibodies against the Delta and Beta strains respectively. Though two doses of the Pfizer vaccine were used, the ELISA-detected anti-Wild-type spike antibodies" in all participants, and neutralizing antibodies against all strains, including the three Variant of concerns (VOCs).

The study also compared how efficient is the vaccine between two doses with the benefits of delaying the second dose (like in the UK and India) and increased individual Neutralizing antibodies (NAbTs). Flagging this as an issue, the study has said, the time delay between two doses should be brought down as the Delta strain is now rapidly spreading.

Market Movers

CompanyPriceChange%Loss
Divis Labs4,313.05 -75.00
Coal India157.15 -2.20
Bajaj Finserv11,798.70 -127.45
Hindalco390.85 -3.95
Dr Reddys Labs5,410.85 -50.50
CompanyPriceChange%Loss
Bajaj Finserv11,799.05 -132.75
Dr Reddys Labs5,414.90 -44.65
Titan Company1,723.50 -11.80
Sun Pharma673.20 -4.05
Bajaj Finance6,160.70 -33.50
CompanyPriceChange%Loss
Divis Labs4,313.05 -75.00 -1.71
Coal India157.15 -2.20 -1.38
Bajaj Finserv11,798.70 -127.45 -1.07
Hindalco390.85 -3.95 -1.00
Dr Reddys Labs5,410.85 -50.50 -0.92
CompanyPriceChange%Loss
Bajaj Finserv11,799.05 -132.75 -1.11
Dr Reddys Labs5,414.90 -44.65 -0.82
Titan Company1,723.50 -11.80 -0.68
Sun Pharma673.20 -4.05 -0.60
Bajaj Finance6,160.70 -33.50 -0.54

Currency

CompanyPriceChng%Chng
Dollar-Rupee73.31250.04250.06
Euro-Rupee88.94300.27100.31
Pound-Rupee103.33400.08400.08
Rupee-100 Yen0.66580.00020.02